BUZZ-Praxis jumps on positive meeting with FDA for tremor drug, epilepsy trial success

Reuters12-05
BUZZ-Praxis jumps on positive meeting with FDA for tremor drug, epilepsy trial success

** Shares of drug developer Praxis Precision Medicines PRAX.O rise 31% to $249.27 premarket

** Co late on Thursday said U.S. FDA has agreed on NDA for its tremor drug, ulixacaltamide

** NDA stands for "New Drug Application"

** Co also reported positive interim results for its rare epilepsy treatment, relutrigine

** "Preliminary checks suggest peak sales could exceed $2.5 billion and sees meaningful catalysts ahead, including NDA acceptance and potential approval in 2026” - Jefferies

** Co's ulixacaltamide showed meaningful benefit for essential tremor, a condition causing involuntary shaking

** Up to last close, stock up ~147% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment